Get the Stockscreener App
8.23
4.44%
0.35
After Hours:
7.30
-0.93
-11.30%
Leonabio Inc stock is traded at $8.23, with a volume of 11,965.
It is up +4.44% in the last 24 hours and down -26.91% over the past month.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
See More
Previous Close:
$7.88
Open:
$7.97
24h Volume:
11,965
Relative Volume:
0.22
Market Cap:
$77.31M
Revenue:
-
Net Income/Loss:
$-129.41M
P/E Ratio:
-0.3416
EPS:
-24.0922
Net Cash Flow:
$-51.97M
1W Performance:
-2.37%
1M Performance:
-26.91%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$7.8091
$8.23
1-Week Range:
$7.8091
$9.36
52-Week Range:
$4.21
$14.21
Leonabio Inc Stock (LONA) Company Profile
Name
Leonabio Inc
Sector
Industry
Phone
(425) 620-8501
Address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare LONA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LONA
Leonabio Inc
|
8.23 | 79.38M | 0 | -129.41M | -51.97M | -24.09 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Leonabio Inc Stock (LONA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-26 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-19-26 | Upgrade | Mizuho | Neutral → Outperform |
| Sep-19-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-04-24 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-04-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Aug-19-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-17-22 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-23-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-23-22 | Downgrade | Jefferies | Buy → Hold |
| Jun-23-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Initiated | BTIG Research | Buy |
| Apr-21-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Goldman | Neutral |
| Oct-13-20 | Initiated | Goldman | Buy |
| Oct-13-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-13-20 | Initiated | Jefferies | Buy |
| Oct-13-20 | Initiated | Stifel | Buy |
View All
Leonabio Inc Stock (LONA) Latest News
LONA Q1 2026 Earnings: EPS Surprises Above Estimates Amid Pre-Revenue PhaseGuidance Accuracy Score - newsline.com
LONA Q1 2026 Earnings: Narrowed Loss Exceeds Expectations as Cost Discipline ContinuesEarnings Trend Analysis - newsline.com
LeonaBio (LONA) Holds Steady Near Support as Sector Sentiment WeighsLow Beta Factor - newsline.com
LeonaBio names brelgometon as INN for ALS drug candidate ATH-1105 - Investing.com UK
LeonaBio names brelgometon as INN for ALS drug candidate ATH-1105 By Investing.com - Investing.com South Africa
LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit - The Manila Times
LONA Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Progress in Pipeline Despite Market HeadwindsMargin Improvement Report - The Legal Advocate
LeonaBio Inc. (LONA) Q1 2026 Earnings: Surprise EPS Beat Signals Progress Despite Revenue GapEstimate Uncertainty - The Legal Advocate
LeonaBio Gets $20 Price Target Ahead of June Pipeline Test - Bez Kabli
LeonaBio Inc. (LONA) Rises 1.45% as Shares Approach Key Resistance at $10.3Stock News - The Legal Advocate
LONA Initiated Coverage by Piper Sandler -- Rating Set to Overwe - GuruFocus
LeonaBio to Participate in Upcoming Medical and Industry Meetings in June - GlobeNewswire
Piper Sandler initiates LeonaBio stock with overweight rating - Investing.com
Piper Sandler initiates LeonaBio stock with overweight rating By Investing.com - Investing.com Canada
LeonaBio Inc. (LONA) Q1 2026 Earnings: EPS Surprise Provides Bright Spot Amid Revenue Absence and Stock DeclineCash Flow Report - The Legal Advocate
LeonaBio Inc. (LONA) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ReactionOperating Income Trends - The Legal Advocate
LeonaBio Inc. (LONA) Q1 2026 Earnings: Narrower-Than-Expected Loss Buoyed by R&D ProgressEarnings Deceleration Risk - newsline.com
LeonaBio Inc. (LONA) Q1 2026 Earnings: Narrowing Losses Signal Operational DisciplineRetail Earnings Report - Newser
Why Is LeonaBio, Inc. (LONA) Stock Up Today? - Meyka
Why Is LeonaBio, Inc. (LONA) Stock Down Today? - Meyka
ADAR1, Daniel Schneeberger disclose 727,481 shares in LeonaBio (ATHA) - Stock Titan
LeonaBio (ATHA) details 2026 director, auditor and Say-on-Pay votes - Stock Titan
Mizuho Securities Maintains LeonaBio(LONA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Dividend HistoryLeonaBio, Inc. (LONA) - Zacks Investment Research
LONA: LeonaBio, Inc.Insider Transations - Zacks Investment Research
MSN Money - MSN
LeonaBio (LONA) director receives 56,000 stock options at $9.63 strike - Stock Titan
Director at LeonaBio (LONA) granted 56,000 stock options - Stock Titan
Option grant gives LeonaBio (LONA) director 56,000 shares at $9.63 - Stock Titan
Natalie Holles named LeonaBio (LONA) director in initial Form 3 - Stock Titan
LeonaBio (LONA) director Peter B. Silverman files initial Form 3 - Stock Titan
LeonaBio (LONA) director Callori Fred files baseline Form 3 ownership report - Stock Titan
Perceptive Advisors (ATHA) caps LeonaBio stake at 19.99% and gains board seat - Stock Titan
LeonaBio (NASDAQ: ATHA) widens loss as R&D ramps for lasofoxifene and ALS drug - Stock Titan
LeonaBio (NASDAQ: ATHA) widens Q1 loss while funding late-stage trials - Stock Titan
LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
LeonaBio reshapes board with 3 hires as long-serving director exits - Stock Titan
LeonaBio John Fluke Retires, Effective May 4 >LONA - Moomoo
LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D. - Weekly Voice
LeonaBio Enhances Board of Directors with Appointments of - GlobeNewswire
LeonaBio, Inc. (LONA) Stock Forecast 2027, 2031 & 7-Year Price Prediction | Meyka AI - Meyka
How sustainable is LeonaBio (LONA) profit margins? (Selling Pressure) 2026-05-06Hot Market Picks - newser.com
LONA Earnings History & Surprises | EPS & Revenue Results | LEONABIO INC (NASDAQ:LONA) - ChartMill
Leonabio Inc Stock (LONA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Leonabio Inc Stock (LONA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Litton Mark James | PRESIDENT and CEO |
Mar 04 '26 |
Sale |
5.37 |
5,156 |
27,688 |
57,926 |
| Renninger Robert | CHIEF FINANCIAL OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
3,900 |
0 |
16,757 |
| Renninger Robert | CHIEF FINANCIAL OFFICER |
Mar 04 '26 |
Sale |
5.37 |
906 |
4,865 |
15,851 |
| Worthington Mark | GENERAL COUNSEL and CCO |
Mar 03 '26 |
Option Exercise |
0.00 |
5,726 |
0 |
19,704 |
| Worthington Mark | GENERAL COUNSEL and CCO |
Mar 04 '26 |
Sale |
5.37 |
1,328 |
7,131 |
18,376 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
5,856 |
0 |
26,537 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Mar 04 '26 |
Sale |
5.37 |
1,359 |
7,298 |
25,178 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
7,418 |
0 |
17,607 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Mar 04 '26 |
Sale |
5.37 |
1,720 |
9,236 |
15,887 |
2.60%
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):